VinFast Auto (NASDAQ:VFS) 주식

VinFast Auto

VinFast Auto Ltd manufactures cars, and motor vehicles, renders leasing activities, trades smartphones, and related businesses. The company is engaged in designing and manufacturing premium EVs, e-scooters, and e-buses. The company's initial EV product line is an all-new range of fully electric A- through E-segment SUVs. The Company has three reportable segments, namely Car, E-scooter and Ebus. The Car segment includes the design, development, manufacturing and sales of cars and related battery lease and battery charging services for cars. The E-scooter segment includes the design, development, manufacturing and sales of e-scooters and related battery lease and battery charging service for e-scooters. The Ebus segment includes the design, development, manufacturing and sales of Ebus.

Vinfast Photo by VanderWolf Images on Shutterstock

News

Tech

베트남의 전기차 제조업체인 빈패스트(NASDAQ:VFS)는 목요일(13일) 전 세계 전기차 판매량이 무려 192% 증가한 97,399대를 기록했다고 발표했다. 

나스닥 상장사 빈패스트, 2024년 인도량 상승 기록했으나 미국 판매량은 알 수 없어

VinFast

Equities

Guidance

Markets

Movers

General

빈패스트 오토(NASDAQ:VFS)의 주식은 회사가 강력한 2024년 4분기 차량 인도량을 발표한 후 목요일 소폭 하락 마감했다. 빈패스트는 공시를 통해 2024년 4분기에 전 세계에서 53,139대의 전기차(EV)를 인도했으며, 이는 전분기 대비 143% 증가하고 전년 대비 342% 증가한 수치라고 밝혔다.

빈패스트의 폭발적인 성장: 야심찬 2025년 목표에 따른 EV 인도량 342% 급증

Ho,Chi,Minh,City,,Vietnam,-,31,Jul,2022.,An

BYDDF

BYDDY

TSLA

베트남의 전기차 제조업체 빈패스트 오토(NASDAQ:VFS)는 2024년 3분기 인도량 증가와 설립자의 막대한 재정적 지원에 힘입어 인도의 성장하는 전기차 시장에 두 가지 프리미엄 SUV를 출시하며 진출한다.

베트남 전기차 제조사 빈패스트, 인도 진출 및 5억 달러 투자 계획

VinFast Auto Ltd

Needham analyst Serge Belanger reiterates Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Buy and maintains $72 price target.

Price Target

Reiteration

Analyst Ratings

CYTK

Needham Reiterates Buy on Cytokinetics, Maintains $72 Price Target

Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice from the staff of the Nasdaq Listing Qualifications Department (the "Staff") notifying the Company that, in accordance with Nasdaq Listing Rule 5101, 5110(b) and IM-5101-1, the trading of the Company's common shares will be suspended at the opening of business on May 20, 2025, and a Form 25 Notification of Delisting will be filed with the U.S. Securities Exchange Commission to delist the Company's securities from The Nasdaq Stock Market ("Nasdaq").

AFMD

Affimed Receives Nasdaq Delisting Notice; Trading To Be Suspended May 20

HC Wainwright &amp; Co. analyst Sameer Joshi maintains Blink Charging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLNK#NASDAQ">BLNK</a>) with a Buy and lowers the price target from $8 to $5.

BLNK

HC Wainwright & Co. Maintains Buy on Blink Charging, Lowers Price Target to $5

Integrated Platform Delivers Enhanced Visibility, Efficiency and Scalability for Forestry Operations
WESTMINSTER, Colo., May 14, 2025 /PRNewswire/ -- Trimble&#xAE; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMB#NASDAQ">TRMB</a>) today launched Trimble Forestry One, a comprehensive technology platform built to connect and streamline forestry operations. Unveiled at the Trimble Forestry User Conference, Forestry One enhances forest management by leveraging Trimble's common data environment for seamless integration with Trimble Connected Forest&#xAE; solutions, while also simplifying regulatory compliance and optimizing supply chain management.

TRMB

Trimble Unveils Forestry One To Connect And Streamline Forestry Operations

On Tuesday, May 13th, U.S. markets closed mixed; the S&amp;P 500 and Nasdaq closed higher for a second day as cooling April inflation and a U.S.-China trade truce boosted investor confidence. The Dow slipped, weighed down by a steep drop in UnitedHealth shares. Traders expect the Fed to hold off on rate cuts until later this year, as recession concerns eased.
According to economic data, April U.S. inflation came in slightly below expectations, with headline CPI and core CPI rising by 0.2% month-over-month. Year-over-year, CPI slowed to 2.3%, while core CPI held steady at 2.8%, matching forecasts.
Six of the S&amp;P 500&#8217;s 11 major sectors ended the day higher, with technology leading the gains. Healthcare was the weakest performer, posting the largest decline.
The Dow Jones Industrial Average declined 0.64% to 42,140.43, the S&amp;P 500 gained 0.72% to 5,886.55, and the Nasdaq surged 1.61% to 19,010.09.
Asia Markets Today
<ul class="wp-block-list">
<li>On Wednesday, Japan&#8217;s Nikkei 225 closed 0.14% lower at 38,130.50, led by losses in the Paper &amp; Pulp, Transport, and Communication sectors.</li>
<li>Australia&#8217;s S&amp;P/ASX 200 gained 0.13%, ending the session at 8,279.60, led by gains in the Energy, IT, and Resources sectors.</li>
<li>India&#8217;s Nifty 50 was up 0.32% at 24,658.40, and Nifty 500 rose 0.60% to 22,483.85.</li>
<li>China&#8217;s Shanghai Composite gained 0.86% to 3,403.95, and the Shanghai Shenzhen CSI 300 was up 1.21% to 3,943.21.</li>
<li>Hong Kong&#8217;s Hang Seng closed the session 2.30% higher at 23,640.65.</li>
</ul>
Eurozone at 05:45 AM ET
<ul class="wp-block-list">
<li>The European STOXX 50 index was down 0.55%.</li>
<li>Germany&#8217;s DAX index declined 0.41%.</li>
<li>France&#8217;s CAC 40 fell 0.64%.</li>
<li>The U.K.&#8217;s FTSE 100 index traded lower by 0.11%.</li>
</ul>
Commodities at 05:45 AM ET
<ul class="wp-block-list">
<li>Crude Oil WTI was trading lower by 1.18% at $62.91/bbl, and Brent was down 1.13% at $65.88/bbl.</li>
<li>Oil prices dipped as traders anticipated a U.S. inventory build, despite support from a U.S.-China tariff pause and easing demand concerns amid broader geopolitical and trade-related developments.</li>
<li>Natural Gas declined 1.81% to $3.581.</li>
<li>Gold was trading lower by 0.26% at $3,239.34, Silver was down 0.44% to $32.953, and Copper fell 0.49% to $4.7000.</li>
<li>Gold prices fell in Asia as easing U.S.-China trade tensions and soft U.S. inflation data reduced safe-haven demand.</li>
</ul>
U.S. Futures at 05:45 AM ET
Dow futures were down 0.04%, S&amp;P 500 futures declined 0.05%, and Nasdaq 100 futures fell 0.03%.
Forex at 05:45 AM ET
<ul class="wp-block-list">
<li>The U.S. Dollar Index declined 0.63% to 101.35, USD/JPY was down 1.15% to 145.81, and USD/AUD fell 0.20% to 1.5421.</li>
<li>The U.S. dollar fell further on Wednesday after weaker April inflation data raised expectations for Fed rate cuts.</li>
</ul>
Photo via Shutterstock

Asia

Emerging Markets

Eurozone

Futures

Commodities

Forex

ADIV

AGOV

ASHR

BBEU

BOIL

CQQQ

PowerShares DBmmodity Index Optimum Yield Diversified Fund

EEMA

FLAX

CurrencyShares British Pound Sterling Trust

IEMG

IEUR

KraneShares Trust KraneShares S&P Pan Asia Dividend Aristocrats Index ETF

KDIV

SPEM

USDU

PowerShares DB US Dollar Index Bullish Fund

Asia Markets Gain, Europe Dips, Dollar Pressured By Soft Inflation Data - Global Markets Today While US Slept

HC Wainwright &amp; Co. analyst Andrew Fein maintains Annexon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANNX#NASDAQ">ANNX</a>) with a Buy and lowers the price target from $20 to $14.

ANNX

HC Wainwright & Co. Maintains Buy on Annexon, Lowers Price Target to $14

Major brokerages have gone back on their U.S. recession forecasts after a<a href="https://www.benzinga.com/government/regulations/25/05/45342343/us-stock-futures-rise-as-us-china-agree-to-90-day-tariff-pause-wider-earnings-growth-should-drive-more-balanced-market-performance-says-expert"> 90-day tariff pause </a>between U.S. and China.
What Happened: Goldman Sachs reduced its U.S. recession odds from 45% to 35%, and Barclays ruled out a recession completely. J.P. Morgan now predicts the likelihood at less than 50%, according to Reuters.
The revised predictions come after both countries agreed to reduce tariffs: the U.S. dropped its duties on Chinese imports from 145% to 30%, and China lowered its rates on U.S. goods from 125% to 10%.
Goldman also raised its 2025 GDP forecast by 0.5 points to 1%. It now projects three Fed rate cuts: one in December 2025, and two more in March and June 2026. Goldman had earlier predicted all three cuts in 2025 beginning from July.
Barclays and J.P. Morgan also now expect a single rate cut, both in December.
Citigroup changed its expected cut from June to July.
In addition, Goldman lifted its S&amp;P 500 year-end target from 5,900 to 6,100, referring to lower tariff risks.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45397930/trump-memecoin-adopted-by-china-linked-nasdaq-company-as-treasury-reserve-asset">Trump Memecoin Adopted By China-Linked Nasdaq Company As Treasury Reserve Asset</a>
Why It Matters: While these major brokerage firms have walked back on their recession predictions after the 90-day pause announcement, analysts like Jim Cramer believe that <a href="https://www.benzinga.com/25/05/45373515/jim-cramer-says-bulls-need-steady-drip-of-trade-deals-to-assure-market-about-recession-and-inflation">"steady drip of trade deals"</a> are crucial to boost the market and allay fears of a recession. 
Google searches for &#8220;Are we in a recession&#8221; have increased to their <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45337839/if-you-have-to-google-are-we-in-a-recession-you-probably-feel-like-it">second-highest level ever</a>, indicating growing public anxiety over the state of the U.S. economy.
Meanwhile, despite coming to a <a href="https://www.benzinga.com/markets/25/05/45374966/xi-jinping-warns-bullying-and-hegemony-will-only-result-in-self-isolation-in-first-remarks-since-us-china-tariff-suspension">tariff pause agreement</a> with the U.S., China is holding firm in its stance against coercion, with President Xi Jinping saying, "There are no winners in tariff wars and trade wars," and that, "bullying and hegemony will only result in self-isolation," obtusely referring to the U.S.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/25/05/45396754/bill-gates-slams-trumps-tariffs-we-told-china-to-make-their-own-chips-and-theyre-making-great-progre">Bill Gates Slams Trump&#8217;s Tariffs: We Told China To &#8216;Make Their Own Chips&#8217; —And &#8216;They&#8217;re Making Great Progress,&#8217; Warns It&#8217;s A &#8216;Bad Time To Interject So Much Uncertainty&#8217;</a></li>
</ul>
Image Via Shutterstock

Economics

Goldman Sachs, Barclays, JPM Walk Back US Recession Forecasts After 90-Day US-China Tariff Truce — Fewer Fed Cuts Expected In 2025

Xenia Hotels &amp; Resorts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XHR#NYSE">XHR</a>) ("Xenia" or the "Company") today announced that its Board of Directors authorized a cash dividend of $0.14 per share of the Company's common stock for the second quarter 2025. The dividend will be paid on July 15, 2025, to all holders of record of the Company's common stock as of the close of business on June 30, 2025.
In addition, the Company's Board of Directors authorized the repurchase of up to an additional $100 million of the Company's outstanding common shares. Repurchases may be made in the open market and privately negotiated transactions, or by other means, including Rule 10b5-1 trading plans. The repurchase program may be suspended or discontinued at any time and does not obligate the Company to acquire any particular amount of shares. Inclusive of this additional authorization, the Company had approximately $180 million remaining under its total repurchase authorization as of May 13, 2025.

Buybacks

Xenia Hotels Declares $0.14 Dividend, Adds $100M to Share Buyback Program

Orezone Gold (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ORE#TSX">ORE</a>) reported quarterly earnings of $0.04 per share. This is a 100 percent increase over earnings of $0.02 per share from the same period last year. The company reported $82.72 million in sales this quarter. This is a 27.87 percent increase over sales of $64.69 million the same period last year.

Earnings

TSX:ORE

Orezone Gold Q1 Adj. EPS $0.04 Up From $0.02 YoY, Sales $82.72M Up From $64.69M YoY

Franklin Street Properties Announced That Its Board Of Directors Has Initiated A Review Of Strategic Alternatives In Order To Explore Ways To Maximize Shareholder Value

Management

TXNM

The Board Of Directors Of Txnm Energy Announced The Transition Of Current Chief Executive Officer Pat Collawn To Executive Chair, Effective July 1, 2025

DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) reported quarterly losses of $(0.12) per share which met the analyst consensus estimate. This is a 40 percent increase over losses of $(0.20) per share from the same period last year. The company reported quarterly sales of $6.75 million which missed the analyst consensus estimate of $7.48 million by 9.68 percent. This is a 17.26 percent increase over sales of $5.76 million the same period last year.

Earnings Misses

DRIO

DarioHealth Q1 Adj. EPS $(0.12), Inline, Sales $6.75M Miss $7.48M Estimate

Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) is looking for FY2026 Adj EPS of $1.56-$1.59 vs $1.54 analyst estimate. sees sales of $1.950 billion-$1.965 billion vs $1.94 billion analyst estimate.

Dynatrace Sees FY2026 Adj EPS $1.56-$1.59 vs $1.54 Est; Sees Sales $1.950B-$1.965B vs $1.94B Est

Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) is looking for Q1 Adj EPS of $0.37-$0.38 vs $0.35 analyst estimate. sees sales of $465.000 million-$470.000 million vs $454.51 million analyst estimate.

Dynatrace Sees Q1 Adj EPS $0.37-$0.38 vs $0.35 Est; Sees Sales $465.000M-$470.000M vs $454.51M Est

Trimble Launched Trimble Forestry One, A Comprehensive Technology Platform Built To Connect And Streamline Forestry Operations

RCAT

Red Cat Announced The Expansion Of Its Multi-domain Family Of Systems With A New Line Of Unmanned Surface Vessels

Howard Hughes Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HHH#NYSE">HHH</a>) surged 2.78% during Wednesday pre-market, after non-Executive Director, Bill Ackman, stepped down from the Board of Directors of Universal Music Group N.V. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UMGNF#OTC">UMGNF</a>). The decision comes in light of new obligations towards Howard Hughes that Ackman has undertaken.
What Happened: As per a press release from Universal Music Group, the music label representing Taylor Swift, Ackman has chosen to resign from his role as a non-executive director with immediate effect. This decision is linked to new executive and board duties resulting from Ackman&#8217;s commitments in Pershing Square Capital Management as well as his recent investments, such as Howard Hughes Holding.
During his tenure at UMG, Ackman witnessed the company&#8217;s transformation from a private entity to a successful public enterprise. He commended the&nbsp;leadership of Sir Lucian Grainge&nbsp;and the UMG team, asserting that the company is &#8220;extremely well positioned for future&nbsp;growth and profitability,&#8221; as per a press release from Pershing Square.
SEE ALSO:&nbsp;<a href="https://benzinga.com/news/25/05/45394734/bernie-sanders-says-american-workers-are-angry-because-wages-havent-kept-up-they-are-lower-today-than-they-w" target="_blank" rel="noreferrer noopener">Bernie Sanders Says &#8216;American Workers Are Angry&#8217; Because Wages Haven&#8217;t Kept Up—&#8217;They Are Lower Today Than They Were 52 Years Ago&#8217;</a>
Why It Matters:&nbsp;Ackman, founder and CEO of Pershing Square, has been a major investor in UMG since 2021. In March this year, his firm <a href="https://www.benzinga.com/25/03/44330386/bill-ackman-sells-portion-of-universal-music-stake-one-of-the-best-businesses-we-have-ever-owned">sold </a>a 2.7% stake in the music company, raising $1.4 billion, after initially acquiring around 10% of UMG.
Ackman&#8217;s belief in UMG&#8217;s long-term growth trajectory has been evident throughout his tenure on the board. In a letter to investors in March, he expressed his confidence in UMG&#8217;s future prospects, citing continued penetration of streaming, recurring price increases, and new product tiers for superfans as the driving factors for the company&#8217;s next era of growth.
Ackman's departure from Universal's board comes on the heels of UMG's Q1 2025 financial results, which reported a 9.5% year-over-year increase in revenue and a 10% rise in adjusted EBITDA at constant currency.
Earlier this month, Ackman <a href="https://www.benzinga.com/news/asset-sales/25/05/45193332/ackmans-900-million-power-play-pershing-square-takes-massive-stake-in-howard-hughes-with-48-premium">increased his stake</a> in real estate firm Howard Hughes Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HHH#NYSE">HHH</a>) to 46.9%, investing an additional $900 million, as part of his goal to build a diversified holding company inspired by Warren Buffett's Berkshire Hathaway (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>).
On Tuesday, the OTC shares of Universal Music Group rose 3.24% to close at $30.94. On a year-to-date basis, it gained 23.91%. 
<ul class="wp-block-list">
<li>READ MORE:&nbsp;<a href="https://benzinga.com/markets/cryptocurrency/25/05/45379271/fartcoin-nets-trader-7-million-in-unrealized-gains-but-he-refuses-to-cash-out-it-is-priming-for-the-move" target="_blank" rel="noreferrer noopener">Fartcoin Nets Trader $7 Million In Unrealized Gains, But He Refuses To Cash Out: &#8216;It Is Priming For THE Move&#8217; &#8211; Benzinga</a></li>
</ul>
Image created using artificial intelligence via Midjourney.
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

UMGNF

Howard Hughes Rises Nearly 3% In Pre-Market As Bill Ackman Exits From Universal Music Group's Board To Prioritize New Investments

Dynatrace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DT#NYSE">DT</a>) reported quarterly earnings of $0.33 per share which beat the analyst consensus estimate of $0.30 by 10 percent. This is a 10 percent increase over earnings of $0.30 per share from the same period last year. The company reported quarterly sales of $445.17 million which beat the analyst consensus estimate of $434.78 million by 2.39 percent. This is a 16.89 percent increase over sales of $380.85 million the same period last year.

Earnings Beats

Dynatrace Q4 Adj. EPS $0.33 Beats $0.30 Estimate, Sales $445.17M Beat $434.78M Estimate

MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) reported quarterly earnings of $0.42 per share which beat the analyst consensus estimate of $0.30 by 40 percent. This is a 10.53 percent increase over earnings of $0.38 per share from the same period last year. The company reported quarterly sales of $261.19 million which beat the analyst consensus estimate of $255.93 million by 2.06 percent. This is a 22.90 percent increase over sales of $212.53 million the same period last year.

MMYT

MakeMyTrip Q4 Adj. EPS $0.42 Beats $0.30 Estimate, Sales $261.19M Beat $255.93M Estimate

<ul>
<li>Potential best-in-class extrahepatic in vivo gene editing with all-in-one delivery to the central nervous system (CNS) is a critical milestone for the treatment of neurological disorders.</li>
<li>Advancements demonstrate the ability to specifically integrate correct copies of complete genes, potentially enabling treatment of any disease caused by a loss-of-function mutation.</li>
</ul>
Key highlights from the company's three poster presentations at ASGCT are below.
<a href="https://www.globenewswire.com/Tracker?data=9yX8a0siWUu86CPPpMs78hcSclIKkQlHcOyOy7e9xdpb2h3iGyDxA83ihILdBnjw1HQHaS2CbxHVuCWMTH0w57JoTAv2b3WeMSuzDqdT4CcFlapWqyMBF4OtT6sLv43f8ShQBhSCiwrTDSwnTmHHUtBm5GdndrKZibF8MLDKDxgXe-5xf4aJnbibP3g4e81XaOMuDKRa2TxPfEm_NspaTMnRTVglZpXZIVLUMECAJfmavFXTHugoE-4vOk0sHhZn">A Compact and Potent Type II CRISPR System for CNS Gene Knockdown via AAV Delivery</a>
<ul>
<li>MG21-1 is a novel, compact type II nuclease comprising 1,098 amino acids that, when delivered with its guide RNA in a single adeno-associated virus (AAV), achieved strong protein knockdown in the CNS.</li>
<li>In vivo, localized injection of AAV9 packaged with MG21-1 in the mouse motor cortex produced up to 69% target protein reduction.</li>
<li>Systemic delivery with a blood-brain barrier-crossing capsid resulted in 82% protein knockdown in the brain and 71% in the brainstem.</li>
<li>These results demonstrate the potential of a small CRISPR nuclease to efficiently knock-down targets in the CNS using a single AAV injected locally or systemically.</li>
</ul>
<a href="https://www.globenewswire.com/Tracker?data=z7WKpuXB4eDrDGOE23u9TFcEu0CtaS12WlveJxpCODdSfO_DwJU_kZyca3RZr6BtxcLv77FA7mqyYZIkfXYFn9WDK3ry-6OthXJ5TEccYich9Lr3Fay3ff-ksWEuaMaRj2k7OCHjEN_WVUht2DXoU0Sd2iAOaDWX-0YXvNCqWe1e-yRRbM52WGTYVEVDAiZ9HL4fTj4Hq8ii5qwuEM3W7Nv383eU3ORRwvJgcICl-CGZvmdc2K2t1vpd-VIe9HW6">In Vivo Genome Editing with an Ultra-Compact Type V Nuclease for All-In-One AAV Delivery&nbsp;</a>
<ul>
<li>MG119-28 is an ultra-compact engineered type V nuclease consisting of 488 amino acids and capable of efficient genome editing across multiple cultured cell tissues when delivered using a single AAV vector.</li>
<li>In vitro, this nuclease restored dystrophin protein levels by over 50% in Duchenne muscular dystrophy (DMD) model myocytes and achieved complete gene disruption at a therapeutically relevant target locus in K562 human cells.</li>
<li>In vivo, AAV9-mediated delivery to the mouse CNS via stereotactic injection resulted in up to 52% editing efficiency in olfactory bulb nuclei and produced 64% knockdown of the target protein in the motor cortex.</li>
<li>These results highlight the potential of this ultra-compact nuclease to deliver AAV-based therapeutic genome editing beyond the liver, with implications for treating neuromuscular and neurodegenerative disorders.</li>
</ul>
<a href="https://www.globenewswire.com/Tracker?data=p5HPOOwWH3cfhRJHO9Y-K3uk7xtoptN2P-I-Www9_TzyMETbO5ScRth_f3PwunltWyzUlub2CaTfszNfEAzlxwoKSwuIsbEhcgIYC3mltru5_nfj2L57QG3kXcrLSOr89Y6hBGwvvM-61OJ-F4MumqlCiRGrmlgknmdNbOlIBvFIA0jfyVANKVxcCRdzVyeL2kl2WJksw2bzP4GxvRxdRsR2oZ_HoPbbdLAesokYtn2sxntNmtcT2DHV2lEbfuxe9l_O_4uyxtR88N8PZWi-IRg_TeGk7riV6SS_fMCaKRrZLxYhSHxG73y8dVqs1mWGWboeMbl2n3WyFksBewIGcQ==">Site-Specific Integration of Therapeutic Transgenes with a Type V-K CAST System Engineered for Efficient and Targeted Human Genome Editing&nbsp;</a>
<ul>
<li>The data demonstrate that CRISPR-associated transposases (CAST) protein engineering and delivery optimization enables efficient integration of diverse cargo designs across different cell types and target loci, including with therapeutically relevant delivery approaches that are required for in vivo editing.</li>
<li>Through structure and AI-guided protein design, integration efficiency of a compact type V-K CAST system derived from uncultivated microbes was improved by &gt;50x compared with the natural system.</li>
<li>Functional activity translated to primary mammalian cells, a key step in development for human therapeutic applications.</li>
<li>These results suggest that type V-K CAST are promising systems for site-specific programmable integration of gene-sized donors for therapeutic and biotechnological development.</li>
</ul>

Biotech

Health Care

Metagenomi Announced The Presentation Of Three Abstracts At The American Society Of Gene & Cell Therapy Annual Meeting

Press Releases

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of VinFast Auto Ltd. - VFS

VINFAST OFFICIALLY LAUNCHES IN THE MIDDLE EAST

Contracts

VINFAST AND DURANGO DRIVERS' UNION SIGN STRATEGIC MOU ON GREEN TRANSITION OF PUBLIC TRANSPORT IN MEXICO

VINFAST BEGINS U.S. DELIVERIES OF VF 9 ALL-ELECTRIC WITH LIMITED-TIME SPECIAL OFFER

VinFast Reports Unaudited Third Quarter 2024 Financial Results

VinFast to Attend the 2025 Canadian International Auto Show

VinFast Reports Fourth Quarter and Full Year 2024 Financial Results

AYRO

Cenntro

Chijet Motor Company, Inc. - Ordinary Shares

Chijet Motor Co

ECD Automotive Design, Inc. - Common Stock

ECD Automotive Design

Envirotech Vehicles

Ford Motor

Faraday Future Intelligent Electric Inc. - Class A Common Stock

Faraday Future

Fly-E Group

General Motors

Honda Motor Co

Lucid Group

Li Auto Inc. - American Depositary Shares

Li Auto

Lotus Technology Inc. - American Depositary Shares

Lotus Technology

NIO Inc. American depositary shares, each representing one Class A ordinary share

NWTN

Polestar Automotive Holding UK Limited - Class A ADS

Polestar Automotive

Polestar Automotive Holding UK Limited - Class C-1 ADS (ADW)

Rivian Automotive, Inc. - Class A Common Stock

Rivian Automotive

Thor Industries

Toyota Motor

Tesla

Winnebago Industries

Workhorse Gr

XPeng Inc. American depositary shares, each representing two Class A ordinary shares

XPeng

ZEEKR Intelligent Technology Holding Limited American Depositary Shares (each representing ten (10) Ordinary Shares)

Comments

VinFast Auto

뉴스

파트너 / 기고자

벤징가 글로벌